Monschein, Tobias http://orcid.org/0000-0002-6053-4210
Salhofer-Polanyi, Sabine
Altmann, Patrick
Zrzavy, Tobias
Dal-Bianco, Assunta
Bsteh, Gabriel
Rommer, Paulus
Berger, Thomas
Leutmezer, Fritz
Article History
Received: 1 June 2020
Revised: 7 July 2020
Accepted: 10 July 2020
First Online: 14 September 2020
Compliance with ethical standard
:
: PA: participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Merck, Roche, Sanofi-Genzyme and Teva. He received honoraria for consulting with Biogen and a combined research sponsorship from Biogen, Merck, Sanofi-Genzyme, Roche, and Teva for the development of a smartphone application for people with MS. He received directed funding from Quanterix International for research studying serum neurofilaments as a biomarker in MS. Thomas Berger: has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Biogen, Bionorica, Celgene, MedDay, Merck, Novartis, Roche, Sanofi Aventis/Genzyme, TG Therapeutics and TEVA. His institution has received financial support in the last 2 years by unrestricted research grants (Biogen, Novartis, Sanofi Aventis/Genzyme, Roche, TEVA) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Roche, Sanofi Aventis/Genzyme, TEVA. Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Roche and Teva. Assunta D-B: has participated in meetings sponsored by or received speaker honoraria or travel funding or unrestricted scientific grants from Biogen, Merck, Novartis and Roche. FL: has participated in meetings sponsored by, received speaker honoraria or travel funding or unrestricted scientific grants from Actelion, Biogen, Celgene, Med Day, Merck, Novartis, Roche, Sanofi-Genzyme, Schering, and Teva. TM: has participated in meetings sponsored by or received travel funding from Biogen, Celgene, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. Paulus Stefan Rommer: received honoraria for lectures or consultancy from AbbVie, Alexion, Allmiral, Biogen, Daiichi-Sankyo, Merck, Novartis, Roche, Sandoz, Sanofi Genzyme, Teva. He received research grants from Amicus, Biogen, Merck, Roche. Sabine S-P: declares no conflict of interest with respect to the study and data presented in this paper. TZ: has participated in meetings sponsored by or received travel funding from Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.
: The study was approved by the ethics committee of the Medical University of Vienna (EK 1203/2016) and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Due to retrospective data collection, no informed consent was obtained.